ACAT2 inhibitor combined with statin

This page covers all ACAT2 inhibitor combined with statin drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting ACAT2 and HMG-CoA reductase.

Targets

ACAT2 and HMG-CoA reductase

Phase 3 pipeline (1)

• Lapaquistat acetate and rosuvastatin · Takeda · Cardiovascular
  Lapaquistat acetate inhibits ACAT2 (acyl-CoA:cholesterol acyltransferase 2) to reduce intestinal cholesterol absorption, while rosuvastatin inhibits HMG-CoA reductase to reduce hepatic cholesterol synthesis.

Patent intelligence

• acat2 inhibitor combined with statin patent landscape — aggregated cliff calendar, attackable patents, originator estates